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The electroencephalographic/magnetoencephalographic (EEG/MEG) signal is generated primarily by the summation of the postsynaptic
currents of cortical principal cells. At a microcircuit level, these glutamatergic principal cells are reciprocally connected to GABAergic
interneurons. Here we investigated the relative sensitivity of visual evoked and induced responses to altered levels of endogenous
GABAergic inhibition. To do this, we pharmacologically manipulated the GABA system using tiagabine, which blocks the synaptic GABA
transporter 1, and so increases endogenous GABA levels. In a single-blinded and placebo-controlled crossover study of 15 healthy
participants, we administered either 15mg of tiagabine or a placebo. We recorded whole-head MEG, while participants viewed a visual
grating stimulus, before, 1, 3 and 5 h post tiagabine ingestion. Using beamformer source localization, we reconstructed responses from
early visual cortices. Our results showed no change in either stimulus-induced gamma-band amplitude increases or stimulus-induced
alpha amplitude decreases. However, the same data showed a 45% reduction in the evoked response component at B80ms. These
data demonstrate that, in early visual cortex the evoked response shows a greater sensitivity compared with induced oscillations to
pharmacologically increased endogenous GABA levels. We suggest that previous studies correlating GABA concentrations as measured
by magnetic resonance spectroscopy to gamma oscillation frequency may reflect underlying variations such as interneuron/inhibitory
synapse density rather than functional synaptic GABA concentrations.
Neuropsychopharmacology advance online publication, 30 January 2013; doi:10.1038/npp.2013.9
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INTRODUCTION
The presence and modulation of neuronal responses within
specific time and frequency bands has been implicated in the
implementation of perception and cognition within the brain.
There is also increasing evidence that the most plausible
mechanism for the generation of temporally organized
network activity is in reciprocally connected neuronal
networks containing mixtures of interconnected glutamater-
gic (excitatory) pyramidal and stellate cells, and GABAergic
(inhibitory) interneurons (Bartos et al, 2007; Traub et al,
1996). However, the neuropharmacological bases of the
spatially summated, population-level, neurophysiological
responses (both evoked and induced) that are recorded
non-invasively in humans with magnetoencephalographic/
electroencephalographic (MEG/EEG) are largely unknown.
In a recent observational study we found that, across
individuals, the frequency of stimulus-induced network
gamma oscillations in primary visual cortex was positively
correlated with the concentration of GABA measured with
edited magnetic resonance spectroscopy (MRS)
(Muthukumaraswamy et al, 2009). However, MRS is an
indirect measure of synaptic GABA function and could be
influenced by a number of anatomical, biochemical/meta-
bolic, or even genetic factors. In this experiment, we wished
to test the hypothesis that modulation of endogenous GABA
levels would modify either the amplitude or frequency of
stimulus-related gamma oscillations in human visual cortex.
To do this, we manipulated endogenous GABA levels using
the drug tiagabine in a set of healthy control participants
in a single-blind crossover design. Tiagabine, used in the
treatment of epilepsy, binds with high affinity and
selectivity to GABA transporter 1 (GAT-1; Borden et al,
1994), the primary GABA reuptake transporter in the
human cerebral cortex (Conti et al, 2004). GAT-1 transpor-
ters are located on both neurons and glia (Minelli et al,
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1995) and their presence at fast-inhibitory GABAA synapses
terminates GABA activity and shapes IPSP activity. The
effect of tiagabine, measurable by microdialysis, is to elevate
the extracellular/synaptic concentration of GABA (Dalby,
2000; Fink-Jensen et al, 1992) and therefore to enhance the
actions of endogenous GABA. The electrophysiological
effect of tiagabine is to enhance evoked inhibitory
postsynaptic current (IPSC) duration without modifying
IPSC amplitude (Roepstorff and Lambert, 1994; Thompson
and Gahwiler, 1992).
To directly measure neuronal activity in humans, we
combined MEG recordings with source estimations using an
experimental paradigm that we have previously demon-
strated to be highly robust to potentially confounding
factors such as day, session, or repetition effects (Muthu-
kumaraswamy et al, 2010). MEG is an ideal technique to
capture higher frequency oscillations as it is more robust to
high-frequency artefact sources such as saccades and neck
muscle artefacts than EEG (Fries et al, 2008; Whitham et al,
2007, 2008; Yuval-Greenberg et al, 2008, 2009). The
principal hypothesis we tested was that modulation of
endogenous GABA levels would modify either the amplitude
or frequency of stimulus-related gamma oscillations.
Subsidiary to that hypothesis, we tested for GABAergic
modulations of several neurophysiological parameters,
including stimulus-induced alpha amplitude decreases and
evoked response components, which are also known to
occur with these stimuli (Muthukumaraswamy et al, 2010).
PARTICIPANTS AND METHODS
Participants, Design, and Stimuli
Eighteen right-handed volunteers (14 men and 4 women)
participated in the experiment after giving informed
consent, with all procedures approved by the UK National
Research Ethics Service (South East Wales). Volunteers
were screened and excluded for personal histories of
neurological and psychiatric disease, current recreational
or prescription drug use, and impaired liver function (by
standard liver function tests). Early in the data collection,
three women volunteers were not able to complete the
experiment after becoming too heavily sedated. From this
point in the data collection, women were excluded from
recruitment, leaving completed data sets from 14 men and 1
woman to analyze (mean age 25.5, range 20–32). All results
and conclusions are similar whether this one woman was
included/excluded from the analysis. Participants were
scanned on 2 separate days, separated by a minimum
7-day washout period, at approximately the same time-of-
day. On each day, an initial ‘pre’ MEG recording was
obtained then participants orally ingested a capsule
containing either placebo or 15mg of tiagabine (Gabitril).
This oral dose is similar to the 16mg used in a PET study by
Frankle et al (2009) and identical to several ongoing
imaging studies by our group. Participants were blinded
to the contents of the capsule and placebo/control session
order was counterbalanced across participants. Following
drug/placebo administration, MEG recordings were ob-
tained from participants at 1, 3, and 5-h time-points. At the
conclusion of every MEG recording, participants completed
several psychological questionnaires including, the Biphasic
Alcohol Effects Scale (Martin et al, 1993), the Subjective
High Assessment Scale (Schuckit, 1980) and asked to
qualitatively report their psychological state.
During each MEG recording, participants sat in a
magnetically shielded room and were presented with a
visual stimulus consisting of a, vertical, stationary, max-
imum contrast, three cycles per degree, square-wave grating
presented on a mean luminance background. The stimulus
was presented in the lower left visual field and subtended 81
both horizontally and vertically. A small red fixation square
was located at the top right-hand edge of the stimulus
and remained on for the entire stimulation protocol
(Muthukumaraswamy, 2010; Swettenham et al, 2009). The
stimulus was presented on a Mitsubishi Diamond Pro 2070
monitor controlled by the Psychophysics Toolbox
(Brainard, 1997; Pelli, 1997). The screen size was 1024 by
768 pixels and the monitor frame rate was 100Hz. The
monitor was outside the magnetically shielded room and
viewed directly from within, at 2.15m, through a cut-away
portal in the shield. The duration of each stimulus was
1–1.5 s followed by 1.5 s of fixation square only. Participants
were instructed to fixate for the entire experiment and, in
order to maintain attention, were instructed to ‘press the
response button as soon as the grating patch disappears’.
Responses slower than 750ms from the termination of the
stimulus triggered a visual warning for participants. In each
recording session, 120 stimuli were presented and partici-
pants responded with their right hand. It took approxi-
mately 10min to complete a session.
MEG Acquisition and Analysis
Whole-head MEG recordings were made using a CTF
275-channel radial gradiometer system sampled at 1200Hz
(0–300Hz bandpass). An additional 29 reference channels
were recorded for noise cancellation purposes and the
primary sensors were analyzed as synthetic third-order
gradiometers (Vrba and Robinson, 2001). Three of the 275
channels were turned off because of excessive sensor noise.
At the onset of each stimulus presentation, a TTL pulse was
sent to the MEG system. Participants were fitted with three
electromagnetic head coils (nasion and pre-auriculars),
which they wore for the entire recording day, and were
localized relative to the MEG system immediately before
and after the recording session. Each participant had a
1mm isotropic MRI scan available for source localization
analysis. To achieve MRI/MEG co-registration, the fiduciary
markers were placed at fixed distances from anatomical
landmarks identifiable in participants’ anatomical MRIs
(tragus, eye centre). Fiduciary locations were verified
afterwards using digital photographs.
Offline, data were first epoched from  1 to 1 s around
stimulus onset and each trial visually inspected for data
quality. Data with gross artefacts, such as, head movements
and muscle clenching were excluded from further analysis.
Reaction times were calculated for each trial relative to the
(variable) offset of each grating stimulus. Any trial where
there was no behavioural responses or a response4750ms
were classified as incorrect responses and excluded from
further analysis. For each participant, we ensured that equal
number of trials, from each recording was used in the
analysis. To achieve this, trials were removed from the end
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of each recording run so that each participant had an equal
number of trials submitted for each condition in the
analysis. Following these trial removal procedures, the mean
number of trials remaining to analyze was 105.5 per
participant (range 82–117).
Three source localizations were performed on each data
set using synthetic aperture magnetometry (Robinson
and Vrba, 1999), one for gamma (30–80Hz), one for alpha
(8–15Hz), and one for evoked responses (SAMerf;
Robinson, 2004). Correspondingly, three global covariance
matrices were calculated for each data set, one for gamma,
one for alpha, and one for SAMerf (0–100Hz). Based on
these covariance matrices, using the beamformer algorithm
(Robinson and Vrba, 1999), three sets of beamformer
weights were computed for the entire brain at 4mm isotro-
pic voxel resolution. A multiple local-spheres (Huang et al,
1999) volume conductor model was derived by fitting
spheres to the brain surface extracted by FSL’s Brain
Extraction Tool (Smith, 2002). Readers unfamiliar with
SAM are referred to several methodological reviews
(Hillebrand et al, 2005; Vrba and Robinson, 2001).
For gamma-band SAM image reconstruction virtual
sensors were constructed for each beamformer voxel and
Student’s t-images of source power changes computed using
a baseline period of  1 to 0 s and an active period of 0 to
1 s, while for alpha-band SAM image reconstruction a
baseline period of  1 to  0.3 s and an active period of
0.3 to 1 s was used. This latter time window was used to
avoid confounding alpha responses with the time-locked
evoked response. After generating the source reconstruction
images, the voxel with the strongest power increase (in the
contralateral occipital lobe) was located for gamma and the
voxel with the strongest source power decrease located for
alpha. The source analysis and peak voxel identification
procedures were carried out separately for each recording as
participants were moved in and out of the MEG between
recordings, which would alter their head position in the
MEG dewar. To reveal time-frequency responses at these
locations, the virtual sensors at these locations were
repeatedly band-passed filtered between 1 and 160Hz at
0.5Hz frequency step intervals, filtering with an 8Hz
bandpass, third-order Butterworth filter (Le Van Quyen
et al, 2001; Muthukumaraswamy et al, 2010). The Hilbert
transform was used to obtain the amplitude envelope and
time-frequency spectra were computed as a percentage
changed from the pre-stimulus baselines for each frequency
band. From these spectra, the peak frequency and amplitude
at that frequency for late gamma amplitude increases
(30–80Hz, 0.3–1 s), early gamma amplitude increases
(30–150Hz, 0.05–0.1 s), and alpha amplitude decreases
(8–15Hz, 0.3–1 s) were quantified by collapsing across the
time dimension and finding the maximal (or minimal for
alpha) frequency. We also checked for confounding effects
of using relative change baselines by computing the average
absolute values of the source amplitude estimates within the
respective time-frequency bins.
For SAMerf, the computed evoked response was passed
through the 0–100Hz beamformer weights to generate
SAMerf images (Robinson, 2004) at 10ms intervals from
50–150ms. The image window (usually 70–80ms or 80–
90ms) with the maximal response in visual cortex was
identified and the maximal voxel selected as the peak
location for further analysis. For this, the evoked field was
computed for this virtual sensor ( 0.2 to 0-s baseline) and
the peak amplitude and latency of the M80 and M150
responses quantified.
For the production of grand-average SAM maps, indivi-
dual SAM images were first spatially normalized onto the
MNI (T1) average brain using FMRIB’s Linear Affine Regis-
tration Tool (Jenkinson and Smith, 2001). This was done by
first obtaining a set of warping parameters by registering
the participant’s anatomical MRI with the average brain and
then applying these parameters to the SAM source power
maps. The grand-average images presented in Figure 2 are
the grand-average across both participants and conditions.
All statistical analyses were performed with a 2 4
repeated-measures ANOVA. For these analyses, there were
main effects of ‘day’, ‘session’, and an interaction term ‘drug’,
presented in that order. Here, the critically important term is
the interaction term, indicative of a tiagabine drug-effect.
It should be noted that for F(1, 14) the critical value is 4.6 and
for F(3, 42) the critical value is 2.82 (alpha¼ 0.05). Standard
errors are used to express variance throughout.
RESULTS
Figure 1 shows summed scores from the subjective high
assessment scale (Schuckit, 1980) that participants com-
pleted at the end of each recording session. This
demonstrates that participants were subjectively strongly
affected by tiagabine. Individual items that showed the
largest increase relative to placebo were ‘feeling of
intoxication’, ‘dizziness’, and ‘drug effect is like alcohol’.
Task response accuracy data showed a significant interac-
tion effect (F(1, 14)¼ 3.71, F(3, 42)¼ 2.34, F(3, 42)¼ 2.99,
po0.041) with post hoc testing showing a weak effect at
3 h for the tiagabine session to have more errors (tiagabine
94.9(2.1) %, placebo 98.5(0.6) %, t(14)¼ 2.99, p¼ 0.06).
Reaction time data showed a main effect of day and an
interaction effect (F(1, 14)¼ 12.7, po0.003, F(3, 42)¼ 0.73,
F(3, 42)¼ 3.11, po0.036). Post hoc tests showed reaction
times were significantly slowed at 3 h (tiagabine 271(17)ms,
placebo 215(13)ms, t(14)¼ 4.719, po0.001) and 5 h (tiaga-
bine 251(20)ms, placebo 208(14) ms, t(14)¼ 3.733,
po0.002) after tiagabine.
Figures 2a–c show grand-averaged source reconstructions
for gamma-band (30–80Hz), alpha-band (8–15Hz) and
Figure 1 Summary of total scores for participants on the subjective high
assessment scale (Schuckit, 1980). The maximum score on this scale is
1300 but varies according to participants’ subjective interpretation of the
instruction set.
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evoked field (80–90ms) responses to presentation of the
grating stimulus and as previously reported (Brookes et al,
2005) these are generated in the medial visual cortex in the
hemisphere opposite to the side of visual stimulation and
closely colocalized. The spatial separation of the peak
locations from each other was approximately 1 cm. Time-
frequency analyses for the gamma-band locations are
presented in Figure 2d, grand-averaged for each day and
recording session, and show the typical component
morphology following this type of visual stimulus. There
is an initial transient broadband (50–100ms) amplitude
increase in the gamma-frequency (430Hz) band (‘early
gamma’), followed by a longer-lasting elevation of gamma-
frequency amplitude in a narrower frequency range (‘late
gamma’). In the lower frequencies, there is an initial
transient onset response, which is a characteristic signature
of the evoked response (Clapp et al, 2006; Muthukumara-
swamy et al, 2010; Swettenham et al, 2009), followed by a
sustained alpha amplitude decrease.
Response components were parameterized (using the
optimal virtual sensor locations for each component) for
each participant and subjected to statistical analysis
(Figure 3). Neither early gamma frequency (F(1, 14)¼ 0.093,
F(3, 42)¼ 2.17, F(3, 42)¼ 0.73) or late gamma frequency
(F(1, 14)¼ 1.42, F(3, 42)¼ 1.16, F(3, 42)¼ 1.70) showed any
significant effects. Similarly, neither early gamma amplitude
(F(1, 14)¼ 0.23, F(3, 42)¼ 0.25, F(3, 42)¼ 1.57) or late gamma
amplitude (F(1, 14)¼ 0.02, F(3, 42)¼ 2.24, F(3, 42)¼ 1.55)
demonstrated any effects. Alpha activity showed some
non-drug specific effects including, alpha frequency show-
ing a main effect of session but no interaction effect (F(1, 14)
¼ 2.32, F(3, 42)¼ 3.58, po0.03, F(3, 42)¼ 0.53), while alpha
amplitude showed a main effect of day effect but no
interaction effect (F(1, 14)¼ 7.78, po0.02, F(3, 42)¼ 0.46,
F(3, 42)¼ 0.93). In addition, we performed similar statistical
analyses on the individual time-frequency ‘pixels’ to look
for subtle time-frequency effects (data not shown) and these
demonstrated similar null effects. Finally, we checked to
see if there were any confounding effects of using relative
change baselines by extracting absolute amplitude
values (no baselining performed) for the various time-
frequency windows. For gamma, no effects were seen for
the early (F(1, 14)¼ 3.57, F(3, 42)¼ 0.87, F(3, 42)¼ 0.14), late
(F(1, 14)¼ 3.30, F(3, 42)¼ 0.15, F(3, 42)¼ 0.26), or baseline
periods (F(1, 14)¼ 1.05, F(3 42)¼ 0.08, F(3, 42)¼ 0.21). For
alpha, no effects were seen in the active (F(1, 14)¼ 3.98,
F(3, 42)¼ 1.41, F(3, 42)¼ 0.67) or the baseline period
(F(1, 14)¼ 0.15, F(3, 42)¼ 0.08, F(3, 42)¼ 0.14).
In Figure 4, the source-level evoked responses are
presented for both tiagabine and placebo. These demon-
strate a clear reduction in the amplitude of the first evoked
response component that occurs just after 80ms (labeled
‘M80’) following tiagabine and an enhanced second
component (labeled ‘M150’). Statistical analysis of the
M80 amplitudes data showed a main effect of day, session,
and critically an interaction effect (F(1, 14)¼ 24.7, po0.001,
Figure 2 (a–c) Grand-averaged source localization of gamma oscillations (30–80Hz), alpha oscillations (8–15Hz), and the visual evoked response
(80–90ms). Units are t-statistics for panels a, b, and arbitrary units for panel c. The peak source location for the gamma-band was at Talairach co-ordinate
[13,  99,  1], [21,  97,  1] for the alpha-band and [15,  89, 1] for the evoked field. Note: in these beamformer images spatial extent of the colour
map does not represent the spatial extent of ‘activation’ (see Barnes and Hillebrand, 2003). (d) Grand-averaged time-frequency spectrograms showing
source-level (gamma peak location) oscillatory amplitude changes following visual stimulation with a grating patch (stimulus onset at time¼ 0). Spectrograms
are displayed as percentage change from the pre-stimulus baseline. Spectrograms were computed for frequencies up to 160Hz but truncated here to
100Hz for visualization purposes.
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Figure 3 Summary of the experimental time courses of oscillatory time-frequency parameters (a–f) in early visual cortex for both tiagabine and placebo
sessions. Early gamma was defined in the range 30–150Hz, 0.05–0.1 s, late gamma was defined in the range 30–80Hz, 0.3–1 s, and alpha in the range
8–15Hz, 0.3–1 s. No oscillatory parameters displayed an interaction effect indicative of a drug effect.
Figure 4 Source-level evoked field analysis for tiagabine (a) and placebo (b). Extracted M80 and M150 amplitudes are presented in (c) and (d),
respectively. Both these parameters showed significant interaction effects; indicating an effect of drug. Note: the negative scaling of (d). The peak latencies of
these responses are summarized in (e) and (f), respectively. These did not show significant interaction effects.
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F(3, 42)¼ 30.9, po0.001, F(3, 42)¼ 13.1, po0.001). M150
amplitudes showed significant effects of day, session,
and an interaction effect (F(1, 14)¼ 7.26, po0.001,
F(3, 42)¼ 3.60, po0.03, F(3, 42)¼ 4.00, po0.02). The M80
latency showed a day effect but no other effects
(F(1, 14)¼ 8.06, po0.02, F(3, 42)¼ 0.49, F(3, 42)¼ 0.14) and
M150 latency showed no significant effects (F(1, 14)¼ 0.14,
F(3, 42)¼ 2.34, F(3, 42)¼ 0.35). No correlations were observed
between the SHAS measures or reaction times and the
evoked field magnitudes and their respective change from
baseline scores.
Finally, we conducted an analysis to check whether there
were any systematic differences in virtual sensor locations that
might potentially have confounded the results. The virtual
sensor locations for gamma, alpha, and evoked response
locations were tested using ANOVA in X, Z, and Z directions.
No significant interaction effects were observed, indicating no
systematic changes in response locations with tiagabine.
DISCUSSION
In the current experiment, we elevated endogenous
GABA in human participants by administering the GAT-1
blocker tiagabine, while measuring evoked and induced
visual responses with MEG. The data showed a clear
modification of visual evoked responses but, contrary to
our hypotheses, we found no alteration in stimulus-induced
oscillatory responses in either the alpha or gamma-
frequency bands. We believe our approach did significantly
increase GABA based on previous PET studies using a
similar dose of tiagabine that show GABA-related changes
in tracer binding (Frankle et al, 2009, 2012; Myers et al,
2012).
One particularly striking feature of the dissociation
between evoked and induced responses is that this
occurred in the same temporal segments of MEG data.
That is, there was a clear reduction in the M80 evoked
response but no alteration in the temporally congruent early
gamma spike (50–100ms). This suggests that these two
MEG responses have different generator mechanisms.
The early gamma response may reflect early ascending
input from the lateral geniculate nucleus (Castelo-Branco
et al, 1998) and is manifested across all cortical layers,
although particularly in layers II and III (Xing et al, 2012),
whereas early evoked responses are mostly generated in
layer IV (Kraut et al, 1985). The pharmacological basis
of this selective modulation presumably lies in the
complex distribution of GABAA and GABAB receptor
subunits across the lamina of V1 (Hendry et al, 1994;
Zilles et al, 2004). In particular, the inhibition provided by
GABAA activation is thought to control response gain to
stimuli in primary visual cortex (Katzner et al, 2011) and to
control the layer-specific spread of excitatory activity
caused by visual stimulation (Olivas et al, 2012). Reduction
of this horizontal spread of excitation (decreased spatial
summation) during stimulation onset may be the mechan-
ism underlying the diminished evoked responses we
have observed.
This selective modulation also suggests other more-
simplistic interpretations of the data are incorrect. For
example, one might argue that the reduction in M80
amplitude is due to reduced task vigilance, attention, or
even fixation control as participants changed psychological
state after tiagabine ingestion. However, each of these
explanations would also be expected to modulate oscillatory
gamma amplitude (Hoogenboom et al, 2010; Kahlbrock
et al, 2012). Similarly, as these dissociable parameters are
all based on the same data, they all have the same relative
signal-to-noise ratio. The 45% peak reduction we
observed in M80 amplitude is significantly larger than
other studies examining visual evoked potentials (VEPs)
with benzodiazepenes that affect GABAergic function. In
all, 20mg diazepam administered intravenously (Loughnan
et al, 1987) or 10mg administered orally (Bartel et al, 1988)
has no effect on the VEP. However, 6 and 12mg of the
benzodiazepine bromazepam has been shown to reduce
ERP components beginning with the N1 (Bauer et al, 1997)
and 10 mg/kg of intravenous midazolam caused a relatively
small reduction in N75-P100 amplitude (van Leeuwen et al,
1992). In fact, it has been shown that tiagabine, which
increases GABA rather than acting via the benzodiazepine
receptor, actually increases the amplitude of early somato-
sensory evoked potential components (Restuccia et al,
2002). The lack of correlation between the subjective
measures in the SHAS and evoked field changes
suggest that the changes in evoked field are not simply
attributable to the arousal state of participants. Another
possibility is that the decreased evoked responses we
observed might be due to decreased fixation control
during the tiagabine-affected conditions. However, loss of
fixation control might be expected to alter the response
location of both retinotopic evoked responses (Di Russo
et al, 2002) and also gamma-band responses as these are
retinotopically organized (Perry et al, 2011). Our analysis of
source peak activity locations indicated no shifts in spatial
location for either of these response components. Further,
the amplitude of gamma-band activity is very sensitive to
the retinotopic position of the stimulus and falls off more
rapidly with eccentricity (Swettenham et al, 2009) than
evoked components. Our gamma-band amplitudes re-
mained unaltered across conditions. Nevertheless, measure-
ment of fixation position via either eye-tracking or
electrooculography would be a useful addition to future
experiments.
Direct manipulation of GABA levels in this experiment
does not appear to have altered gamma frequency, and
potential reasons for this are worth considering. It is
possible that the lack of effect in the oscillatory domain is
due to a lack of statistical power, or perhaps because an
inadequate dose of tiagabine was given. However, we do not
believe that it would be ethically or feasibly possible to give
a much higher dose to control participants and still have
them complete the required tasks given the profound
behavioural and subjective effects on participants. We also
note that overall data quality was very high, with gamma
activity identifiable in every subject. Further, although there
is no guarantee that raising GABA levels with this dose of
tiagabine has a direct effect on the synaptic (eg, time
constants) properties of neurons in visual cortex, this is
unlikely since similar doses have been shown to change
11C-flumazenil and 11C-Ro15 4513 binding potentials
(Frankle et al, 2009, 2012; Myers et al, 2012). In addition,
tiagabine-induced increases in GABA could potentially
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modulate GABAergic synapses on all neuronal subtypes,
including pyramidal cells and inhibitory interneurons, and
receptor subtypes (GABAA (six subtypes) and GABAB) with
unpredictable effects on oscillatory dynamics until the role
of all these GABA receptors is elucidated.
In a previous study we found, across individuals, that the
frequency of stimulus-induced network gamma oscillations
in primary visual cortex was positively correlated with the
concentration of GABA measured with MRS. MRS measures
the total bulk of GABA in a given area of the brain (usually
from a rather large voxel, eg, 27 cm3). Consistent with
invasive evidence, MRS returns concentrations of GABA in
the millimolar range (Puts and Edden, 2012). In the synaptic
cleft, GABA concentration can reach the millimolar range
(Mody et al, 1994) but this rapidly declines (o1ms).
Although estimates for ambient levels GABA in the
extracellular space range from tens of nanomolar to
micromolar (Farrant and Nusser, 2005) these are still
orders of magnitude less than the total bulk of GABA.
Therefore, MRS measures of GABA concentration probably
depend on interneuron numbers/inhibitory synapse num-
bers, and/or the rate constants of glutamic acid decarbox-
ylase, GABA transaminase, and GAT-1. In particular,
interneuron density/synapse numbers, which are inherently
structural parameters (Schwarzkopf et al, 2012), would not
be susceptible to short-term pharmacological manipula-
tions, as we have attempted here.
Although our specific hypothesis was not confirmed, the
data here are promising for the relatively unexplored field
of pharmaco-MEG (Hall et al, 2010). We note another very
recent study using the cholinergic agonist phystostigmine
found a selective modulation of alpha oscillation amplitude
(but not gamma) in response to visual stimuli in humans
with MEG (Bauer et al, 2012). These studies therefore
demonstrate that MEG can noninvasively characterize the
effect of pharmacologically targeted and physiologically
selective agents using alterations in quantitative neuronal
biomarkers. Future studies systematically investigating the
pharmacological sensitivity of MEG responses will allow the
development of data-driven pharmacological models of
these responses. Given the wide range of safe and selective
interventional agents that can be safely administered to
interact with neurotransmitter systems, this bodes well for
our future understanding of the neuropharmacological
basis of MEG/EEG.
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